Amedisys Stock Today

AMED Stock  USD 90.16  0.16  0.18%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 10

 
High
 
Low
Low
Amedisys is trading at 90.16 as of the 22nd of November 2024, a 0.18 percent increase since the beginning of the trading day. The stock's lowest day price was 89.78. Amedisys has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Amedisys are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of November 2023 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain
Health Care Equipment & Services
IPO Date
17th of August 1994
Category
Healthcare
Classification
Health Care
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana. Amedisys operates under Medical Care Facilities classification in the United States and is traded on NASDAQ Exchange. The company has 32.75 M outstanding shares of which 2.26 M shares are presently shorted by private and institutional investors with about 5.97 trading days to cover. More on Amedisys

Moving against Amedisys Stock

  0.67DOCS DoximityPairCorr
  0.6MD Mednax IncPairCorr
  0.6VREX Varex Imaging CorpPairCorr
  0.59OM Outset MedicalPairCorr
  0.54ECOR Electrocore LLCPairCorr
  0.48DXCM DexCom IncPairCorr

Amedisys Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEO PresidentRichard Ashworth
Old NameAmedeo Resources Plc
Business ConcentrationHealth Care Providers & Services, Health Care Equipment & Services, Health Care, NASDAQ Composite, SP Midcap 400, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Health Care Providers & Services, Medical Care Facilities, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover2.011.0855
Way Up
Slightly volatile
Gross Profit Margin0.190.2044
Significantly Down
Slightly volatile
Total Current Liabilities497.4 M473.7 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total490 M466.7 M
Sufficiently Up
Slightly volatile
Total Assets2.2 B2.1 B
Sufficiently Up
Slightly volatile
Total Current Assets521.8 M496.9 M
Sufficiently Up
Slightly volatile
Debt Levels
Amedisys can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Amedisys' financial leverage. It provides some insight into what part of Amedisys' total assets is financed by creditors.
Liquidity
Amedisys currently holds 487.21 M in liabilities with Debt to Equity (D/E) ratio of 0.53, which is about average as compared to similar companies. Amedisys has a current ratio of 1.04, suggesting that it is in a questionable position to pay out its financial obligations when due. Note, when we think about Amedisys' use of debt, we should always consider it together with its cash and equity.

Change In Cash

88.97 Million
Amedisys (AMED) is traded on NASDAQ Exchange in USA. It is located in 3854 American Way, Baton Rouge, LA, United States, 70816 and employs 19,000 people. Amedisys is listed under Health Care Providers & Services category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.95 B. Amedisys conducts business under Health Care Providers & Services sector and is part of Health Care industry. The entity has 32.75 M outstanding shares of which 2.26 M shares are presently shorted by private and institutional investors with about 5.97 trading days to cover. Amedisys currently holds about 17.96 M in cash with 137.19 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.55.
Check Amedisys Probability Of Bankruptcy
Ownership Allocation
Amedisys holds a total of 32.75 Million outstanding shares. The majority of Amedisys outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Amedisys to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Amedisys. Please pay attention to any change in the institutional holdings of Amedisys as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Amedisys Ownership Details

Amedisys Stock Institutional Holders

InstituionRecorded OnShares
Mackenzie Investments2024-09-30
694.6 K
Magnetar Financial Llc2024-06-30
615.5 K
Geode Capital Management, Llc2024-06-30
560 K
Dimensional Fund Advisors, Inc.2024-09-30
509.3 K
Cresset Asset Management, Llc2024-06-30
455.9 K
Sand Grove Capital Management Llp2024-06-30
435.1 K
Qube Research & Technologies2024-06-30
412.3 K
Cnh Partners, Llc2024-06-30
400.4 K
Calamos Advisors Llc2024-06-30
397.3 K
Vanguard Group Inc2024-09-30
3.2 M
Blackrock Inc2024-06-30
3.1 M
View Amedisys Diagnostics

Amedisys Historical Income Statement

At present, Amedisys' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 2.3 B, whereas Gross Profit is forecasted to decline to about 447.4 M. View More Fundamentals

Amedisys Stock Against Markets

Amedisys Corporate Management

Already Invested in Amedisys?

The danger of trading Amedisys is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Amedisys is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Amedisys. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Amedisys is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Amedisys is a strong investment it is important to analyze Amedisys' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amedisys' future performance. For an informed investment choice regarding Amedisys Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.35)
Earnings Share
2.52
Revenue Per Share
71.004
Quarterly Revenue Growth
0.057
Return On Assets
0.0627
The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.